Search companies

Live

Tuesday, 17 November 2026 · 581 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Avecho resumes final-stage recruitment for pivotal insomnia trial as licensing talks advance

AVE: $0.015 +7.14% · MC: $46M

Avecho Biotechnology has restarted recruitment for the final cohort of its Phase III insomnia trial after an interim review recommended continuing to the study’s original target; the company expects recruitment to take about a year. Avecho says licensing discussions with multiple parties for markets outside Australia are progressing, while its cash position was $5 million at quarter-end.

Source announcements: 2026-10-28 09:40 to 2026-10-28 09:40 Sydney time
Story updated 2026-10-28 09:46 Sydney time
SourcesSeptember 2026 Quarterly Activities Report & Appendix 4C
Comments